ANTI-TUBERCULOSIS DRUG RESISTANCE IN ETHIOPIA: A MATA- ANALYSIS by gebremichael, lemlem gebremedhin et al.
Gebremichael et al                                Journal of Drug Delivery & Therapeutics; 2014, 4(3), 154-163 154 
© 2011-14, JDDT. All Rights Reserved                                                    ISSN: 2250-1177                                           CODEN (USA): JDDTAO 
 
Available online at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
© 2014, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original 
work is properly cited 
 
RESEARCH ARTICLE 
ANTI-TUBERCULOSIS DRUG RESISTANCE IN ETHIOPIA: A MATA- ANALYSIS 
Gebremichael Lemlem Gebremedhin1*, Fanta Biruk Sintayehu2, Abay Solomon Mequanente3, Subas Chandra Dinda4 
1Pharmacology and Toxicology course and research unit, Department of pharmacy, college of health sciences, Mekelle 
University 
2Pharmacognosy Course and Research Unit, Department of Pharmacy, College of Health Sciences, Mekelle University 
3Pharmacology department, Faculty of Medicine, Addis Ababa University 
4 Department of Pharmaceutics, C.H.S., Mekelle University, Mekelle, Ethiopia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
Tuberculosis (TB) is the most frequent cause of death. 
About 8.4 million people develop active tuberculosis 
every year and 2.3 million die of it. It is estimated that 
200 million additional people are at risk of developing 
the disease in the next 20 years, if the current trends are 
conserved. 1 
Report from 183 countries shows that there are 3.8 
million cases of TB (62 per 100,000 populations) around 
the world. Nearly 42% of these cases are sputum smear 
positive. The global incidence of TB is growing at 0.4% 
each year. More rapid growth was observed in sub-
Saharan Africa due to the spread of HIV and in countries 
of the former Soviet Union.  Treatment success under 
Directly Observed Treatment Short course (DOTS) for 
the 2000 cohort was 82% on average and it is below the 
average (72%) for African region.2 The DOTS strategy 
has been the principal response to the global TB 
epidemic for the past decades. DOTS programmes 
between the start of 1995 and the end of 2001 diagnosed 
more than ten million patients. Of these over five million 
were smear positive.2By the end of 2001, DOTS had 
been adopted by 155 countries and was available to 61% 
of the world Habitants. Ethiopia’s National Tuberculosis 
and Leprosy Control Program (NTLCP) began to 
implement DOTS in two zones (Arsi and Bale) in 1991. 
In 2007, WHO reported that DOTS coverage reached 
95% of the population. However, while treatment is 
integrated into general health services and due to the 
limited health infrastructure in the country, only 
approximately 60 to 70% of the population has access to 
DOTS services. The DOTS detection rate remains low, 
at 28%, compared with world health organization’s 
(WHO’s) target of 70% detection. The limited diagnostic 
capacity for TB in the country remains a challenge to 
improving case detection rates. The treatment success 
rate is close to the 85% target set by WHO; after falling 
from 80% in 2000 to 70% in 2003, it rose to 84% in 
2007.3 
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ABSTRACT 
Tuberculosis is one of the most dangers of health in the world. Ethiopia ranked seventh from the 22 high burden counties in 
the world. The main problem is development of resistance to the major anti-tuberculosis drugs actually increasing in Ethiopia. 
The aim was to review studies done on anti-tuberculosis drug resistance in Ethiopia. Literatures were searched for published 
articles on anti-tuberculosis drug resistance using the combination of terms; resistance, anti-tuberculosis and Ethiopia. Fifteen 
studies done in different parts of Ethiopia from 1978-2005 G.C were retrieved without restriction of place & design of study. 
The primary resistance of the fifteen studies done in various parts of Ethiopia (Addis Ababa, Harar, Bahir Dar, Sidamo, Arsi, 
and Hosanna) from1978-2005 G.C showed: Isoniazid (H) 1.9%-21.4%, Streptomycin (S) 1.9%-26%, Rifampicin (R) 0%-
1.9%, Ethambutol (E) 0%-6.3%, Thiacetazone (T) 2.2%-6.3%, H+S 1.9%-26%, H+T  0%-4.4%, S+T 0%-1.8%, H+R 0%-
1.1%, S+R 0%-0.7%, R+T 0%-0.4%, H+E 0%-0.9%, S+E 0%-0.6% ,H+S+T 0%-2.4%, H+S+R 0%-1.1%, H+T+R 0%-0.4%, 
H+S+E 0%-1.7%, R+H+T+S 0%-0.6% and Multi Drug Resistance 0%-1.3%.Acquired drug resistance: H 5.3%-66.7%, S 
1.2%-46%, R 0%-12%, E 0%-5.6%, T0%-29%, H+T 0%-20%, H+S 4.8%- 28%,  R+H 0%-8%, R+S 0%-3.5%, S+T 0%-
2.3%, H+E 0%-3.6%, R+E 0%-5.6%, S+E 0%- 11.2%, H+S+T 0%-16%, R+S+T 0%-2.3% , R+S+H 0%-4%, H+S+E 0%-
3.6%, H+R+E 0%- 3.6%, H+R+S+E 0%-14.3% and Multi Drug Resistance 0%-26.3%. It can be concluded that resistance to 
the anti-tuberculosis drugs is increasing. National level drug resistance survey is recommended to design policies and 
strategies to prevent increase of drug resistance. 
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The burden of TB in Ethiopia is one of the highest in the 
world. There are 22 countries that are labelled by WHO 
to carry 80% of the estimated number of all new TB 
cases(all forms) of the world TB and Ethiopia ranks 
seventh among the world’s 22 high-burden tuberculosis 
countries and third from African countries.4,5In Ethiopia, 
According to the ministry of health (MOH) hospital 
statistics data, tuberculosis is the leading cause of 
morbidity, the third cause of hospital admission (after 
deliveries and malaria), and the second cause of death 
(after malaria). According to the WHO’s Global TB 
Report 2009, the country had an estimated 314,267 TB 
cases in 2007, with an estimated incidence rate of 378 
cases per 100,000 population with a mortality rate of 79-
deaths/100,000 population/year.3 
Tuberculosis is caused by mycobacterium primarily 
mycobacterium tuberculosis in human. It is broadly 
classified in to: Pulmonary TB which is infectious and 
the most frequent form of the disease, accounts for 85% 
of all TB cases and Extra-pulmonary TB that results 
from spread of TB to other organs accounting 14% of all 
TB cases in the world. TB can affect any part of the body 
.6, 7 
The major problem with treatment of TB is the 
development of resistance (decrease in susceptibility of 
sufficient degree from a wild strain that has never been 
exposed to the drug) .8, 9,10There are two types of 
resistance: primary resistance that is resistance to any 
drug is developed by some strain without prior exposure 
to that drug and acquired resistance :mainly man made 
problem for development of resistance that is caused by 
non-compliance by the patient and by medical 
practitioners that include long period of treatment (6-12 
months), complex drug prescription, costs of treatment, 
long waits in health facilities, belief of the patient on the 
drug and health professionals, mental illness, use of 
alcohol, substance abuse, and homelessness.11 
The numbers of TB cases are also increasing as 
Ethiopia’s HIV/AIDS epidemic expands; while 16% of 
notified TB patients tested for HIV, 40% are HIV 
positive. The level of multidrug-resistant TB (MDR-TB) 
(TB that is resistant at least to INH and RMP) among 
new TB cases is estimated at 20%.  Five thousand nine 
hundred seventy nine cases of MDR-TB were reported in 
2007.3 
To prevent the development of resistance combination 
therapy is used in TB treatment in two phases: intensive 
phase and continuation phase. The drugs used for 
treatment are grouped in to two depending on 
availability, efficacy, cost and toxicity: first line drugs, 
(isoniazide(INH)(H), rifampicin (RMP) (R), 
pyraziniamide (PZM) (Z), ethambutol (EMB) (E) and 
streptomycin (STM) (S)) 12,13and second line drugs, 
Aminoglycosides: e.g., amikacin, kanamycin; 
Polypeptides: e.g., capreomycin, viomycin, enviomycin; 
Fluoroquinolones: e.g., ciprofloxacin, levofloxacin, 
moxifloxacin; Thioamides: e.g. ethionamide, 
prothionamide; cycloserine (the only antibiotic in its 
class); p-aminosalicylic acid.14 The aim of this study is to 
review all the studies done on anti-tuberculosis drug 
resistance in Ethiopia. 
2. METHODOLOGY 
PUBMED, MEDLINE and HINARI were searched for 
published articles on anti-tuberculosis drug resistance 
using the combination of terms; anti-tuberculosis, 
resistance, and Ethiopia. National journals were also 
searched manually in different libraries; Ethiopian 
medical journals, Ethiopian pharmaceutical journals and 
Ethiopian journal of health development for anti-
tuberculosis drug resistance in Ethiopia without 
restriction of place, year and design of study. 
Fifteen studies done in different parts of Ethiopia (Addis 
Ababa, Harar, Bahirdar, Arsi, Sidamo, and Hosanna) 
from 1978-2005 G.C regarding anti-TB drug resistance 
were retrieved. The results of the different studies were 
obtained from published national journals; Ethiopian 
medical journals, Ethiopian pharmaceutical journals, 
Ethiopian journal of health development and some 
unpublished MSC thesis from Addis Ababa University. 
The results of the different studies done in different 
period and in various parts of Ethiopia were summarized 
in the form of tables and figures.  The different drugs 
used in various studies were included according to the 
year of study. In this review; the number of isolates, year 
of study, study site and the percentage of resistance to 
the anti-tuberculosis drugs used in that study were also 
included. Any drug resistance, according to this review, 
means resistance to one or more anti-tuberculosis drugs. 
Re-treatment cases were considered as acquired 
resistance in this review.  
3.  RESULTS 
Results of the various studies done in different parts of 
Ethiopia were summarized according to their year of 
study, the drugs included, the number of strains isolated 
and the percentage of resistance for single drug and drug 
combinations. The percentages of resistance (primary 
and acquired, any drug and more than two drugs) of each 
included drug were summarized in tables and figures. 
The Fifteen studies done in different parts of Ethiopia 
(Addis Ababa (A.A), Harar, Bahir Dar, Sidamo, Arsi, 
and Hosanna) from1978-2005 G.C showed that the 
primary resistance of Isoniazid ranges from 1.9% to 
21.4%, Streptomycin from 1.9% to 26%, Rifampicin 
from 0% to 1.9%, Ethambutol from 0% to 6.3%, 
Thiacetazone from 2.2% to 6.3%,  H+S from 1.9% to 
26%, H+T from 0% to 4.4%, S+T from 0% to 1.8%, 
H+R from 0% to 1.1%, S+R from 0% to 0.7%, R+T 
from 0% to 0.4%, H+E from 0% to 0.9%, S+E from 0% 
to 0.6% H+S+T from 0% to 2.4%, H+S+R from 0% to 
1.1%, H+T+R from 0% to 0.4%, H+S+E from 0% to 
1.7%,  for R+H+T+S from 0% to 0.6% and MDR ranges 
from 0% to 1.3% (Table-1). 
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Table 1: Summary of primary drug resistance in different cities of ETHIOPIA, 1981-2005 G.C. 
Year 
of 
study 
Study 
site 
No. of  
Isolates 
Resistance (%) MDR  
% 
 Study   type Reference 
1981 A.A 182 H(15),S(5),T(4),R(1),H+S(5),H+T(4),H+S+T(2) 0 Retrospective 16 
1986 A.A/ 
Harar 
276 H(11.9),S(9.4),T(2.2),R(1.1),H+S(6.1),S+T(1.8), 
H+R(1.1),S+R(0.7),R+T(0.4),H+S+T(1.4), 
H+S+R(1.1),H+T+R(0.4) 
1.1 Prospective 17 
1989 Sidamo 104 H(1.9),S(1.9),R(0),E(0),H+S(3.8),H+R(0), 
R+S(0),R+E(0),H+E(0) 
0 Cross-
sectional 
18 
1994 A.A 167 H(8.4),S(10.2),T(6.0),R(1.8),E(0),H+T(2.4), 
S+T(0.6),R+H(0.6),R+S(0.6),S+T+H(2.4), 
R+S+T+H(0.6) 
0.6 Cross-
sectional 
20 
1994/5 Harar 252 H(21.4),S(20.2),T(6.3),R(1.6),E(6.3),H+T(4.4), 
R+H(0.4),S+H(9.9),S+T(1.2),R+S(0.4), 
H+T+S(1.6),R+S+T(0) 
0.4 Cross-
sectional 
21 
1998 Arsi 176 H(2.3),S(11.4),T(1.1),R(0)E(0),H+S(2.8), 
H+R(0),H+S+T(0.5) 
0 Cross-
sectional 
24 
1998 A.A 179 H(8.4),S(7.3),E(0),R(0.6) 0.6 Cross-
sectional 
38 
2001 A.A 103 H(8.7),S(7.8),R(1.9),E(0.9),H+S(1.9),H+E(0.9), 
E+R(0),H+R+S(0.9) 
0.9 Cross-
sectional 
25 
2001 Bahirdar 76 H(3.9),S(15.8),E(0),R(1.3),H+R+S(1.3) 1.3 Cross-
sectional 
26 
2002 Hosanna 27 H(20),S(13.3),E(0),R(0),H+S(7.4) 0 Cross-
sectional 
27 
2004/5 A.A 73 H(5.5),R(1.4),S(26),E(2.7),S+H(26),H+S+E(1.4) 0 Cross-
sectional 
29 
2004/5 A.A 173 H(13.3),S(16.2),R(1.2),E(3.5),H+S(7.5), 
S+E(0.6),H+R+S(0.6),H+S+E(1.7) 
0.6 Cross-
sectional 
30 
 
Table 2: Summary of acquired drug resistance in different cities of ETHIOPIA, 1978-2002 G.C. 
Year of 
study 
Study site No. of 
Isolates 
Resistance (%) MDR   
% 
Study type Ref 
1978 Addis 
Ababa 
184 H(46),S(46),T(29),H+T(20), 
H+S(28),H+S+T(16) 
0 Cross-sectional 15 
1994/5 Harar 86 H(44.2),S(31.4),R(0),T(8.1), 
E(0),H+T(5.8),R+H(3.5), 
H+S(23.2),S+T(2.3), 
R+S(3.5),H+T+S(2.3), 
R+S+T(2.3),R+S+H(0) 
3.5 Cross-sectional 21 
1996 Addis 
Ababa 
113 H(47),S(31),R(11.5),E(2.6), 
H+S(22),H+E(0.9),H+R(8), 
H+S+R(3.5),H+S+E(1.8) 
11.5 Cross-sectional 22 
1998 Arsi 19 H(5.3),R(0),S(10.5),T(0), 
E(0),H+S(15.7),H+R(0), 
H+S+T(0) 
0 Cross-sectional 24 
1998 Addis 
Ababa 
107 H(44),S(28),R(12),E(2), 
H+S(19),H+R(8),H+R+S(4) 
12 Cross-sectional 19 
2001 Addis 
Ababa 
18 H(5.6),R(5.6),E(5.6),S(5.6), 
H+S(5.6),H+E(0),R+E(5.6), 
H+R+S(0) 
0 Cross-sectional 25 
2001/2 Addis 
Ababa 
84 H(7.1),E(2.4),S(1.2),H+R(2.4H+S(4.8),H
+E(3.6),R+E(3.6),S+E(11.2),H+R+S(6), 
H+R+E(3.6),H+S+E(3.6) 
H+R+S+E(14.3) 
26 Cross-sectional 28 
2002 Hosanna 3 H(66.7),S(0),E(0),R(0), 
H+R(0),S+R(0),R+E(0) 
0 Cross-sectional 27 
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The acquired resistance of Isoniazid ranges from 5.3% to 
66.7%, Streptomycin from 1.2% to 46%, Rifampicin 
from 0% to 12%, Ethambutol from 0% to 5.6%, 
Thiacetazone from 0% to 29%, H+T from 0% to 20%, 
H+S from 4.8% to 28%, R+H from 0% to 8%, R+S from 
0% to 3.5%, S+T from 0% to 2.3%, H+E from 0% to 
3.6%, R+E from 0% to 5.6%, S+E from 0% to 11.2%, 
H+S+T from 0% to 16%, R+S+T from 0% to 2.3% 
R+S+H from 0% to 4%, H+S+E from 0% to 3.6%, 
H+R+E from 0% to 3.6%, for H+R+S+E ranges from 
0% to 14.3% and MDR ranges from 0% to 26.3% 
(Table-2). 
The study carried in Addis Ababa TB center in 1978 to 
asses acquired drug resistance in 184 isolates of M. 
tuberculosis showed that the resistance to isoniazid 
(INH) and streptomycin (STM) was 46% each. Twenty 
nine percent was for thiacetazone (THA). Double drug 
resistance ranged 20-28% (INH+THA=20% and 
INH+STM=28%) and triple drug resistance was 15% 
(INH+THA+STM) (Table-3andTable-4).15 
 
Table 3: SUMMARY OF ACQUIRED RESISTANCE OF ANY DRUG IN DIFFERENT CITIES OF ETHIOPIA, 
1994/5-2002 G.C. 
   Year of study Study site No. of isolates Any drug resistance % Study type Reference 
1994/95 Harar 86 51.2 Cross-sectional 21 
1996 Addis Ababa 113 51 Cross-sectional 22 
1998 Arsi 19 31.6 Cross-sectional 24 
1998 Addis Ababa 107 50 Cross-sectional 19 
2001 Addis Ababa 18 33.6 Cross-sectional 25 
2001/2 Addis Ababa 84 53.6 Cross-sectional 28 
2002 Hosanna 3 66.7 Cross-sectional 27 
 
Table 4: SUMMARY OF ACQUIRED RESISTANCE OF MORE THAN TWO DRUGS IN DIFFERENT CITIES OF 
ETHIOPIA, 1978-2002 G.C. 
Year of study Study site No. of 
isolates 
More than two drugs 
resistance (%) 
Study type Reference 
1978 Addis Ababa 184 64 Cross-sectional 15 
1994/5 Harar 86 42.9 Cross-sectional 21 
1996 Addis Ababa 113 36.2 Cross-sectional 22 
1998 Arsi 19 15.7 Cross-sectional 24 
1998 Addis Ababa 107 31 Cross-sectional 19 
2001 Addis Ababa 18 11.2 Cross-sectional 25 
2001/2 Addis Ababa 84 42.9 Cross-sectional 28 
2002 Hosanna 3 0 Cross-sectional 27 
 
In 1981 a study was done in 182 isolates from newly 
diagnosed TB patients of Addis Ababa in Addis Ababa 
TB center. Of the 182 isolates 15% were INH resistant, 
5% STM resistant, 4% THA resistant, 1% RMP resistant, 
5% were resistant to INH+STM, 4% to INH+THA and 
2% to INH+THA+ STM (Table-1,5&6).16 
 
Table 5: SUMMARY OF PRIMARY RESISTANCE OF ANY DRUG IN DIFFERENT CITIES OF ETHIOPIA, 
1981-2005 G.C. 
Year of study Study site No. of 
isolates 
Any drug 
resistance % 
Study type Reference 
1981 Addis Ababa 182 14.8 Retrospective 16 
1986 Addis Ababa/ Harar 276 15.2 Prospective 17 
1989 Sidamo 104 7.6 Cross-sectional 18 
1994 Addis Ababa 167 15.6 Cross- sectional 20 
1994/5 Harar 252 32.5 Cross-sectional 21 
1998 Arsi 176 19.5 Cross-sectional 24 
1998 Addis Ababa 179 12.9 Cross-sectional 38 
2001 Addis Ababa 103 14.6 Cross-sectional 25 
2001 Bahir Dar 76 18.4 Cross-sectional 26 
2002 Hosanna 27 22.2 Cross-sectional 27 
2004/5 Addis Ababa 73 17.8 Cross-sectional 29 
2004/5 Addis Ababa 173 21.4 Cross-sectional 30 
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Table 6: SUMMARY OF PRIMARY RESISTANCE OF MORE THAN TWO DRUGS IN DIFFERENT CITIES OF 
ETHIOPIA, 1981-2005 G.C. 
Year of study Study site No. of 
isolates 
More than two drugs 
resistance (%) 
Study type Reference 
 
1981 Addis Ababa 182 11 Retrospective 16 
1986 Addis Ababa/ 
Harar 
276 13 Prospective 17 
1989 Sidamo 104 3.8 Cross-sectional 18 
1994 Addis Ababa 167 7.2 Cross-sectional 20 
1994/5 Harar 252 17.9 Cross-sectional 21 
1998 Arsi 176 3.3 Cross-sectional 24 
2001 Addis Ababa 103 3.7 Cross-sectional 25 
2001 Bahir Dar 76 1.3 Cross-sectional 26 
2002 Hosanna 27 7.4 Cross-sectional 27 
2004/5 Addis Ababa 73 27.4 Cross-sectional 29 
2004/5 Addis Ababa 173 10.4 Cross-sectional 30 
 
In 1985 a study was carried out in Addis Ababa and 
Harar, involving all the TB centers, in 276 M. 
tuberculosis isolates who had never taken any previous 
ant-tuberculosis chemotherapy.  The prevalence of 
primary drug resistance was 15.2% (42/276). Of the 42 
resistant isolates; 8 were resistant to three drugs; 31 to 
two drugs (in both instances, combination of INH, STM, 
THA and RMP); 23 were resistant to a single drug. All 
strains were found to be sensitive to EMB and PZM. 
RMP resistance was observed in 1% of the isolates from 
Addis Ababa, not Harar (Table-5 & 6).17 
In 1987 a cross sectional study was done in Sidamo 
regional hospital to assess primary resistance of 104 
isolates of tubercle bacilli. The result showed that 
resistance to one or more ant- TB drugs was found to be 
7.6%.  Two strains (1.9%) showed resistance to INH and 
STM each. Four strains (3.8%) showed double drug 
resistance to the same drugs (INH+STM). None were 
resistant to THA, RMP and EMB (Table-1).18 
In 1993/94study was done in 107 strains isolated from 
retreatment cases of tubercle bacilli from Addis Ababa 
TB demonstrating and training center to determine 
acquired drug resistance and it was found that the 
prevalence of resistance to one or more of the first line 
drugs was about 50%; 44% was resistant to INH, 28% to 
STM, 12% to RMP and 2% to EMB; 19% was resistant 
to INH+STM, 8% to INH+RMP, and 4% to 
INH+RMP+STM. MDR was 12%. All MDR strains 
were susceptible to amikacin, ciprofloxacin, ethambutol, 
ethionamide and clofazimine (Table-4, 6& Fig-1).19 
A study was done in 1994 in Addis Ababa (including all 
hospitals, health centers and six of the nine clinics in 
Addis Ababa) with 167 isolates of M .tuberculosis to 
assess the susceptibility of these strains to the anti-TB 
drugs. Of the 167 isolates 84.4% (141/167) showed no 
resistance to any drugs tested. Overall primary resistance 
involving one or more drugs was found to be 15.6% 
(26/167); primary resistance to two or more drugs was 
7.2% (12/167) (Table-6). When each drug was 
considered, the highest rates of resistance was observed 
for STM (10.2%) and INH (8.4%), followed by THA 
(6%) and RMP (1.8%). Resistance to INH+THA was 
2.4%, STM+THA, RMP+INH, RMP+STM was 0.6% 
each. Resistance to EMB was nil. MDR was low (0.6%) 
(Fig-2).20 
 
 
Figure 1: PERCENTAGE ACQUIRED MDR-TB IN 
ADDIS ABABA 
 
Figure 2: PERCENTAGE PRIMARY MDR-TB IN 
ADDIS ABABA 
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In 1994/95 a cross sectional study was done to determine 
the initial and acquired resistance of 338 isolates of M 
.tuberculosis in Harar TB center. The overall prevalence 
of resistance to one or more anti-TB drug was 37.3% 
(126/338). Initial resistance was 32.5% (82/252) while 
that of acquired resistance was 51.2% (44/86). Primary 
resistance to INH was 21.4%, 20.2% to STM, 1.6% to 
RMP, 6.3% to THA and 0.4% to EMB. Acquired 
resistance to INH was found to be 44.2% followed by 
STM 31.4%, THA 8.1%, RMP 5.8% and EMB 0% 
(Table-1& 2).21 
A study was done in 1995/6 in Addis Ababato assess the 
acquired resistance of 113 isolates of tubercle bacilli 
from Addis Ababa patients to first line, second line and 
experimental drugs. Of the 113 isolates 47% (53/113) 
were resistant to INH, 31% (35/113) to STM, 11.5% 
(13/113) to RMP, and 2.6% (3/113) to EMB. All isolates 
resistant to RMP were MDR isolates. Most MDR isolates 
(9/13) were susceptible to STM and all were susceptible 
to EMB.22Among the 28 isolates resistant to the four first 
line drugs, 96% (27/28) were resistant to clarithromycin, 
96% (27/28) to THA, 64% (18/28) to cycloserine & PAS 
(para-amino salicylic acid) and 36% (10/28) to rifabutin. 
Twenty one (84%) out of 25 isolates resistant to first line 
drugs was susceptible to amikacin, ciprofloxacin, 
clofazimine, and ethionamide. MDR was seen in 11.5% 
(13/113) of the isolates. Seven of these MDR isolates 
were isolated from chronic excreters (patient who remain 
acid fast smear positive after completing a retreatment 
regimen.23 Four from cases with relapse (who were cured 
in the past but again have active TB),23 one from a 
defaulter (patient who discontinued treatment for at least 
one month)11 and one from a patient who was smear 
positive after five months of treatment (Table-2).  
In 1997/98 a study was done in Arsi zone to determine 
primary and acquired resistance of 195 isolates of M. 
tuberculosis. Among 195 isolates, 175 (90.2%) never 
had prior treatment to anti-TB drugs and 19 (9.7%) had 
had prior treatment to anti-TB drugs for a mean duration 
of one month. The overall resistance level to one or more 
anti-TB drugs was 38/195 (19.5%). Of the 176 isolates 
32/176 (18.2%) was primary resistance and 6/19 (31.6%) 
was acquired resistance. Primary resistance to INH and 
STM were 2.3% and 11.4% respectively. Of the 19 
patients who had prior treatment resistance to INH was 
5.3% and 10.5% to STM. Primary and acquired MDR-
TB was nil. Mono-resistance to RMP and EMB was nil 
(Table-1 &2).24 
In 2001 a study was done in Addis Ababa at Tikur 
Anbesa hospital to assess acquired and primary drug 
resistance of 121 isolates of M. tuberculosis in patients 
with and without HIV infection. In total, 17 of 
121isolates (14.0%) were resistant to one or more of the 
anti-tuberculosis drugs.  INH resistance was 8.3%, STM 
7.4%, RMP 2.5%, and EMB 1.7% (Table-1&2).25 
The study carried out in 2001, at two health institutions 
(felegehiwot hospital and Bahirdar health center) in 
Bahir Dar  showed that of the 76 strains isolated from 
newly diagnosed patients, primary mono-resistance was 
highest to STM (14.5%) followed by INH (2.6%). In this 
study all isolates were susceptible to RMP and EMB. 
Primary resistance to any was found in 18.4% of new TB 
patients; and any primary resistance to STM was 15.8%; 
3.9% was to INH; to RMP was 1.3% and nil for EMB. 
The rate of primary MDR was 1.3% (Table-1, 5&Fig-
2).26 
The study done in Hosanna in 2002 showed that of the 
total 30 isolates; 8 (26.6%) were resistant to one or more 
anti-TB drugs. Primary and acquired resistances were in 
6 of the 27 strains (22.2%) and in 2 of the 3 strains 
(66.7%) respectively. MDR-TB was nil in both primary 
and acquired drug resistant cases. Drug resistances were 
observed in INH (20%) and STM (13.3%). All the strains 
were sensitive to RMP and EMB. Poly resistance 
involving only INH and STM was observed (Table-1 
&2).27 
In 2001/2002 a study in St. Peter TB specialized Hospital 
was done to determine the anti-TB drug resistance 
among retreatment patients. Among the 84 isolates 
tested, resistance to at least one drug was observed in 45 
(53.6%) of them. The highest rate of resistance was 
observed against INH with 38.1% isolates resistant and 
5.9% partial resistant. Resistance to RMP was found in 
29.8% of the isolates. Nineteen percent of the isolates 
were resistant and 10.7% partially resistant to STM. 
Resistance and partial resistance to EMB was seen in 
8.3% and 23.8%, respectively. Twenty six point three 
percent of the isolates were MDR. Resistance to two 
drugs was observed in 13 (15.5%), to three drugs in 11 
(13.1%) and four drugs in 12 (14.3%) of the patients. 
Mono-resistance was observed in 9 (10.7%) patients, of 
which 6 were against INH (Table-3, 4&Fig-1).28 
In 2004/2005 study was performed assessing the 
susceptibility of 73 isolates of M. tuberculosis taken 
from smear negative (37) and smear positive (36) 
patients visiting St. Peter TB Specialized Hospital. Of 
the 37 isolates, 29.8% (11/37) showed resistance to any 
of the drugs tested. Mono-resistance was found only for 
STM in 9 (24.3%) isolates. Resistance to INH, EMB and 
RMP accounted for 1 (2.7%) each. Resistance to two or 
more drugs was observed in 5/37 (13.5%) strains.  
Resistance to any drug was observed in 27.4% (20/73) of 
the isolates. The resistance rate to INH, RMP, STM, and 
EMB was 5.5% (4/73), 1.4% (1/73), 26% (19/73) and 
2.7% (2/73), respectively. Resistance to INH+STM was 
26% (19/73), 1.4% (1/73) to INH+STM+ EMB. No 
MDR strains were observed in this study (Table-1, 5 & 
6).29 
In 2004/2005 a study was conducted to assess the 
primary drug resistance in newly diagnosed smear 
positive TB patients visiting 19 health centers and 3 
hospitals in Addis Ababa. Among the M. tuberculosis 
strains isolated from 173 patients, 21.4% were resistant 
to at least one drug; single drug resistance to STM was 
observed in 16.2%, to INH in 13.3%, to RMP in 1.2% 
and to EMB in 3.5% of the isolates. The prevalence of 
resistance to at least one drug was 15.7% and 23.7% 
among patients with and without HIV co-infection, 
respectively. The prevalence of resistance to more than 
one drug was 10.4% (Table-1, 5 &6).30 
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4. DISCUSSION  
As can be seen from the results described above, from 
different parts of Ethiopia, anti-TB drug resistance 
especially in the retreatment cases is increasing in spite 
of introduction of DOTS to different parts of the country. 
Mono resistance to INH and STM is increasing in very 
high speed with time. This leads to development of 
resistance to EMB and RMP (MDR-TB) when INH is 
given with one of these drugs in the continuation phase 
due to mono therapy.  Increase in STM resistance also 
increases poly resistance that endangers the existing 
drugs (Table-1 and 2). 
A high mono-resistance rate facilitates the emergence of 
MDR-TB31; emergence of MDR-TB facilitates extended 
drug resistance (XDR) (MDR-TB that is resistant to 
quinolones and also to any one of the injectable drugs; 
kanamycin, capreomycin, or amikacin).32to occur. In 
previously treated patients in DOTS implementing areas, 
MDR-TB could emerge in a sequential manner; i.e., 
initial resistance to INH or STM is amplified to double 
STM and INH resistance; initial resistance to INH or 
RMP is amplified to double INH and RMP resistance 
and so on and finally to MDR-TB and XDR-TB.31,33 The 
rate of MDR-TB is increasing in spite of DOTS 
implementation in Ethiopia as can be seen from the 
figures specially acquired MDR-TB (Fig-1). In general 
resistance to the first line anti-tuberculosis is increasing 
with time as can be seen from the different studies done 
in Ethiopia. Patients with INH resistance receiving INH 
and EMB in the continuation phase will undergo EMB 
mono-therapy resulting in development of EMB 
resistance. EMB is a bacteriostatic drug with low 
efficacy that may not effectively prevent development of 
resistance to INH. Patients with INH resistance receiving 
INH and RMP in the continuation phase will undergo 
RMP mono-therapy resulting in development of RMP 
resistance that leads to MDR-TB. 
Even though the number of patients involved, the method 
of sensitivity test, design of study, place of study, area of 
coverage etc., differ from one study to the other, the 
various studies carried out in various parts of Ethiopia at 
different time, showed that generally the danger of 
resistance to the existing anti-TB drugs is increasing 
which leads to shifting to the more expensive, more 
toxic, less effective, unavailable drugs and finally to 
untreatable  and  facing difficulty of controlling the 
disease. 
The study done in 1978 showed high acquired resistance 
to INH (46%), STM (46%), and THA (29%).15 All this 
resistance was suggested to come from treatment failure 
(could be from inadequate dose, non-compliance, 
inappropriate prescription, inappropriate combination) 
and relapse cases (the patient is obtained to be smear 
positive after he/she is declared cured of the disease). 
The prospective study done in Harar and Addis Ababa in 
1985 showed that the prevalence of primary resistance to 
one or more drugs was 15.2% which was comparable to 
the previous studies.16Resistance to rifampicin was 
obtained from the strains isolated from Addis Ababa 
patients (but not from Harar) unlike similar strains 
isolated from the same area in the earlier studies.15 This 
could be due to the high resistance to isoniazid that was 
widely available in private and government health 
institutions, was quite generally prescribed alone or in 
combination unlikely to be effective by non- professional 
or untrained practitioners throughout the country.  No 
resistance was encountered to ethambutol or 
pyrazinamide because these drugs were recently 
introduced in the treatment of TB in Ethiopia. In this 
study it was noted that thiacetazone, either alone or in 
combination, showed a low resistance rate, despite its 
wide use throughout Ethiopia.17 
The study done in Sidamo regional hospital showed that 
the rate of resistance to one or more anti-TB drugs was 
7.6% which was lower than the earlier recorded results in 
other area16, 17 which in general was of the order of 15%. 
In this area resistance rate to two combined drugs 
(INH+STM) and to three combined drugs 
(INH+STM+THA) was low and nil, respectively. This 
finding along with similar studies confirms the fact that 
primary drug resistance in general seems not to pose a 
major problem for the success of chemotherapy in 
tuberculosis. This is so because failure to respond to 
standard chemotherapy occurs in patients resistant to two 
or more drugs (low in this study) than in those resistant 
to one drug.23 
The other study that showed high resistance to the anti-
TB drugs was the study done in Harar TB center in 
1994/95. In this study the prevalence of primary drug 
resistance was 32.5% which was higher as compared to 
the previous studies done in this country that ranged 
between 7.5% and 15.2%.16,17 This high rate of resistance 
might be due to high defaulter rate, shortage of anti-TB 
drugs in government sector, availability of anti-TB drugs 
in open market which were smuggled from neighboring 
countries, unsupervised treatment and the practice of 
inappropriate prescriptions made by the private clinics in 
this area. War, displacement, drought and frequent 
population movements with disruption of health 
infrastructures might have contributed to the high 
prevalence resistance rate. Although initial/primary and 
acquired resistance to rifampicin were low (1.6%, 5.8%, 
respectively), no rifampicin resistance was reported 
previously in Harar region.17This showed that resistance 
to rifampicin is increasing. In addition, the high 
resistance to isoniazid in both new and re-treatment cases 
of TB and the prevalence of MDR in 3.5% of re-
treatment cases denotes that further delay in 
implementing DOTS and inadequate supervision may 
endanger the control of TB.34 Initial resistance to 
streptomycin was higher when compared to the previous 
reports.15-18 This may be due to the wide spread abuse of 
streptomycin in this area, sputum smear examinations 
were not routine in many of the health facilities; 
therefore patients were started on standard regimen 
empirically. The frequent shortage of streptomycin that 
was observed has led to the increased cost of 
streptomycin that could not be afforded by many patients 
in this area.21and streptomycin was prescribed to treat 
other infectious diseases too; that increase development 
of resistance to this drug.  
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The study done in Arsi zone showed that the overall rate 
of resistance was 19.5% which was lower than the 
previous study done in Harar that was 37.3%.21This was 
due to relatively well-organized control programme in 
this area. The acquired drug resistance was 31.6% that 
was lower than the previous studies done in Ethiopia.19, 
15, 21
This was because in this area DOTS were 
implemented, and the control program was relatively 
efficient. The primary resistance was obtained to be 
18.2% whereas the earlier study in Harar showed 
32.5%.21The accessibility of anti-TB drugs, supervised 
treatment, and the wide practice of treating tuberculosis 
patients in the health institutions with the recommended 
diagnosis, treatment and follow up procedures might 
have contributed to the low rate of primary drug 
resistance. Primary drug resistance rate observed to 
isoniazid in this study (2.3%) was lower than the 
previous studies done in TB centers, which showed 12%, 
21.4% in 1981 and in 1994/5 respectively.16, 21 This may 
reflect that patients coming to the health institutions were 
more likely to have not received prior anti-TB treatment 
as compared to the patients coming to tuberculosis 
centers. Single drug resistance to streptomycin was 
highest in this study. Overall the tendency of drug 
resistance to streptomycin seems increasing in recent 
years.16,20-21 This is thought to be related to the past wide 
spread use of streptomycin as antibiotic in the treatment 
of infectious disease other than tuberculosis. The absence 
of resistance to rifampicin alone and in combination with 
isoniazid, in this study, may probably indicate that these 
drugs were properly used in this area.  
The study done in 2001/02 in Addis Ababa showed that 
53.6% of the strains were resistant to the first line anti-
TB drug among the retreatment cases.28 The result of this 
study is comparable with a similar study on re-treatment 
cases in Addis Ababa that showed 50% of the strains to 
be resistant to one or more of the first line drugs.19 
Overall resistance to isoniazid was found to be 49.3%. It 
tops the list compared to the other three drugs: 
rifampicin, streptomycin, and ethambutol. This figure is 
not very different from the results of the previous 
studies. This study however, showed an increase in 
resistance to rifampicin and ethambutol. The high rate of 
resistance to rifampicin could be associated with a 
number of factors: previous availability of loose 
rifampicin and its extensive use for TB and other 
infectious diseases, non-compliance and single drug 
administration. It is possible that patients with HIV 
infection may have altered absorption (malabsorption) 
for rifampicin that might lead to the development of 
rifampicin resistance35 though the status of the patients of 
this study was not known. In this study MDR-TB was 
observed in 26.3% of the patients. This is relatively high 
compared with previous reports 3.5%21 and 12%19 
among re-treatment cases (Fig-1).  The reason for this 
high multi drug resistance could be due to the high 
rifampicin resistance which is increasing with time. 
The study done in Addis Ababa pulmonary tuberculosis 
patients in 2004/05 showed that the overall resistance 
rate involving one or more drugs was 27.4% which was 
higher than those in the previous studies in Ethiopia (14-
22.3%).17, 20, 25,36 The resistance rate for isoniazid was 
5.5% which is within the range 1.9%-21.4%.16-17, 20-
21,25The primary resistance rate for streptomycin was 
26% which is higher than all studies done in Ethiopia 
from 1978-2005 G.C. this can be explained as 
streptomycin was widely in use for treatment of other 
bacterial infections and patterns of inadequate treatment 
of tuberculosis patients, either due to lack of drugs or 
poor compliance by patients (defaulters); both in turn 
selecting drug resistant mutant strains. Although 
rifampicin is used currently for the treatment of many 
other infectious diseases and sold all over Ethiopia, the 
level of resistance was still very low (1.4%). The rate is 
slightly higher than the previous studies done in Ethiopia 
(0-1.9%).17, 20, 24-25Resistance to ethambutol   (2.7%) in 
this study is within the range 0%-6.3% 16, 17, 21of the other 
studies done in Ethiopia. 
From all the fifteen studies reviewed only two studies 
were done on anti-tuberculosis drug resistance among 
patients with and without human immunodeficiency 
virus (HIV) co-infection. From these studies, on 
comparison between HIV positive and negative patients, 
no association was observed between drug resistance 
among new cases and HIV co-infection. This could be 
failure to identify any association; because HIV co-
infected patients with drug resistant TB might have died 
earlier than HIV negative patients with drug resistant 
TB.37 This phenomenon could also explain the higher 
proportion of drug resistance in HIV negative patients 
than in HIV positive patients (23.8% vs15.7%).38 
Additional reasons could be that HIV positive patients 
with drug resistance might have been missed because 
they tend to be smear negative, default or die 
undiagnosed. 
5. LIMITATIONS OF THE STUDY 
The studies reviewed here were done in various parts of 
the country with varied climatic conditions, culture, 
understanding etc., at different period. Some of the 
studies included TB/HIV co-infection, but most of the 
studies do not. Different numbers of strains were isolated 
using various methods of isolation, sensitivity testing 
methods, including different areas of coverage and health 
institutions (tuberculosis centers, hospitals, health centers 
and clinics) were used in the studies reviewed.  
6. CONCLUSION and RECOMMENDATION 
The review of different studies carried out in various 
parts of Ethiopia showed that anti-tuberculosis drug 
resistance is increasing and becoming concern to 
patients, health professionals and to the population in 
general. 
It is understandable that the management of MDR-TB 
cases is very difficult and might involve expensive drugs. 
The management of these cases mainly depends on the 
in-vitro susceptibility pattern of the infecting isolate to 
the first and second lines drugs. The availability of 
second line drugs in the free market could easily lead to 
the amplification of resistance and might even make the 
management, at a later time, more difficult case even to 
the emergence of XDR-TB. Therefore, this may not 
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seem to be a priority to control programs in low-income 
countries like Ethiopia where HIV/AIDS prevalence is 
high. So this should be the time when MDR-TB should 
be properly addressed and managed when the cases are 
few, before it spreads and many people come up with 
primary MDR-TB.  For this purpose, the development of 
new and cheap drugs is essential and could be done by 
screening drugs which are being used for other clinical 
conditions, by screening traditionally used medicines or 
by producing novel drugs that can inhibit multiplication 
of the resistant strains and their transmission to others.  
 In the studies done in Ethiopia it has been shown that 
ethambutol resistance is increasing but still low. This is 
an advantage that should be exploited in order to develop 
a regimen for the management of MDR-TB. This can be 
considered as an important finding since almost all MDR 
strains of M .tuberculosis isolated in Ethiopia are 
susceptible to ethambutol. 
To manage and prevent the present trend in Ethiopia: 
national level anti-tuberculosis drug resistance survey, 
strict control of compliance of patients and health 
professionals, good infrastructure, strict rules and 
policies to prevent selling of drugs without prescription 
especially the second line drugs that are available in the 
open market,  periodic drug surveillance, further study 
including HIV status, strong management of tuberculosis 
control with development of policies, public awareness 
about transmission and resistance development and its 
consequences, strengthening of laboratory capacity 
throughout the regions and urgent need for a newer, 
more effective vaccine that would prevent all forms of 
TB; including drug resistant strains in all age groups and 
among people with HIV are recommended. 
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